Miyachi Y, Wee S L, Chen L K, Grumet F C, Bowman R J, Taurog J D
Hum Immunol. 1984 Aug;10(4):237-49. doi: 10.1016/0198-8859(84)90089-2.
A cytolytic human T cell (CTL) clone, designated F/M-F159, has been produced, the lytic specificity of which distinguishes subtypes of HLA-B27. This was demonstrated in cell-mediated lympholysis (CML) assays of: 1) a panel of target cells from unrelated donors, 75 B27 + and 36 B27-; 2) six families, including 20 B27 + and 14 B27- individuals; and 3) B27 + and B27- variants of a B27+ lymphoblastoid cell line (LCL). Specificity of F/M-F159 for HLA-B27 was confirmed by blocking studies with monoclonal antibodies. Lysis of B27 + targets reactive with the anti-B27 monoclonal antibody B27M2 was 30-104%, while lysis of B27 +, B27M2- targets was 4-22%. Lysis of B27- targets expressing HLA-Bw47, known to be cross-reactive with the B27M2 antibody, was 10 to 19%, while lysis of all other B27- targets was less than or equal to 10%. Clone F/M-F159 lysed B27 + targets, and failed to lyse B27- targets, irrespective of the clinical status of the cell donors. It is concluded that F/M-F159 recognizes an epitope present on the majority of serologically identified HLA-B27 molecules and that this epitope is closely related to, but not identical with, the epitope recognized by the antibody B27M2. These findings are interpreted as supporting a direct role for HLA-B27 in disease pathogenesis.
已产生一种细胞溶解性人T细胞(CTL)克隆,命名为F/M-F159,其溶细胞特异性可区分HLA - B27的亚型。这在以下细胞介导的淋巴细胞溶解(CML)试验中得到了证实:1)一组来自无关供体的靶细胞,75个B27阳性和36个B27阴性;2)六个家族,包括20个B27阳性和14个B27阴性个体;以及3)一个B27阳性淋巴母细胞系(LCL)的B27阳性和B27阴性变体。用单克隆抗体进行的阻断研究证实了F/M-F159对HLA - B27的特异性。与抗B27单克隆抗体B27M2反应的B27阳性靶细胞的裂解率为30 - 104%,而B27阳性、B27M2阴性靶细胞的裂解率为4 - 22%。表达已知与B27M2抗体有交叉反应的HLA - Bw47的B27阴性靶细胞的裂解率为10%至19%,而所有其他B27阴性靶细胞的裂解率小于或等于10%。克隆F/M-F159裂解B27阳性靶细胞,而不裂解B27阴性靶细胞,与细胞供体的临床状态无关。得出的结论是,F/M-F159识别大多数血清学鉴定的HLA - B27分子上存在的一个表位,并且这个表位与抗体B27M2识别的表位密切相关,但不相同。这些发现被解释为支持HLA - B27在疾病发病机制中起直接作用。